CLEARSIDE Research and Clinical Development PROGRAMS

THERAPEUTIC

MECHANISM

INDICATION

CURRENT STATUS

THERAPEUTIC, MECHANISM, INDICATION, STATUS, PARTNER

CLS-AX (axitinib)

Tyrosine Kinase Inhibitor

Wet AMD

Undisclosed

Improve choroidal perfusion

Geographic Atrophy (GA)

Undisclosed

Modulate pro-inflammatory cells

Geographic Atrophy (GA)

Commercial Asset: XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use

THERAPEUTIC

LOCATION

INDICATION

CURRENT STATUS / PARTNER

THERAPEUTIC, LOCATION, INDICATION, STATUS, PARTNER

XIPERE®

United States

Uveitic Macular Edema1

XIPERE® / ARCATUS™

Australia and Singapore

Uveitic Macular Edema2

XIPERE® / ARCATUS™

China

Uveitic Macular Edema2

XIPERE® / ARCATUS™

Asia Pacific (ex-Japan)

Diabetic Macular Edema2

SCS Microinjector® Partner Clinical Development Programs

THERAPEUTIC

TYPE

INDICATION

CURRENT STATUS / PARTNER

THERAPEUTIC, TYPE, INDICATION, STATUS, PARTNER

Bel-Sar

Viral-like Drug Conjugate

Choroidal Melanoma

ABBV-RGX-314

AAV Gene Therapy

Diabetic Retinopathy

ABBV-RGX-314

AAV Gene Therapy

Wet AMD

Avoralstat

Plasma Kallikrein Inhibitor

Diabetic Macular Edema

Footnotes:

1XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use has received U.S. FDA Approval and is being commercialized by Bausch + Lomb.

2In China, Arctic Vision is responsible for clinical development of ARCATUS™ (triamcinolone acetonide injectable suspension), formerly referred to as ARVN001, and known as XIPERE® in the U.S.